Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576051 · ClinicalTrials.gov registry record
To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 9,159
- Enrollment target
NCT05576051: Completed study, sponsored by Pfizer.
NCT05576051 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 9,159 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05576051 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 9,159 participants
- Enrollment target
Study Summary
To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.
Primary Outcome
CDAI was a simplified index for assessing the disease activity comprising of the swollen joint counts (SJC), tender/painful joint counts (TJC), participant's global assessment of disease activity (PtGA) and physician's global assessment of disease activity (PGA). CDAI is the numerical sum of 4 outcome parameters: SJC and TJC (based on 28-joint assessment range from 0 to 28, higher scores indicated worse condition), PtGA and PGA (score range from 0 to 10, assessed on 0-10 centimeter (cm) visual a
Interventions
- OTHER patterns of use of combination therapy and monotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9,159 participants |
| Start Date | 2015-06-04 |
| Est. Completion | 2015-10-07 |
What the finished NCT05576051 record still lists
NCT05576051 is an observational study that tracks outcomes without assigning an intervention. Its 9,159 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which patterns of use of combination therapy and monotherapy is the first listed.
NCT05576051 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05576051 about?
NCT05576051 is a clinical study titled "To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.". To estimate the efficacy of treatment with TNFi as monotherapy or combination therapy with MTX and compare and contrast efficacy with Tofacitinib as monotherapy and combination therapy in a real world setting.
What is the current status of trial NCT05576051?
This trial is currently completed. The enrollment target is 9,159 participants. The study started on 2015-06-04. Estimated completion is 2015-10-07.
What interventions are being tested in trial NCT05576051?
The interventions under investigation include: patterns of use of combination therapy and monotherapy (OTHER).
Who is sponsoring clinical trial NCT05576051?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06946355 · 9,119 participants · NA
Food-based Support for Hospitalized Children and Their Families
- NCT02000089 · 9,000 participants · Phase 3
The Cancer of the Pancreas Screening-5 CAPS5)Study
- NCT05612347 · 8,946 participants · NA
Colonoscopy vs Stool Testing for Older Adults With Colon Polyps
- NCT06284408 · 9,460 participants · NA
Centralized Screening Unit (CSU) at Montefiore-Einstein
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI